Pari Tablets (Generic Paroxetine Hydrochloride Tablets)

Pari Tablets (Generic Paroxetine Hydrochloride Tablets)
© The Swiss Pharmacy

Pari (Generic Paroxetine Hydrochloride Tablets) is a selective
serotonin reuptake inhibitor (SSRI) used in adults to treat
mental health conditions like depression, anxiety, Major
Depressive Disorder (MDD), Obsessive Compulsive Disorder
(OCD), Panic Disorder (PD), Generalised Anxiety Disorder
(GAD), Social Anxiety Disorder (SAD), Post-Traumatic Stress
Disorder (PTSD) and Premenstrual Dysphoric Disorder
(PMDD).

Pari Tablets are manufactured by IPCA Laboratories Limited,
India in the strength of 10 mg, 20 mg, 30 mg and 40 mg.

Chemical Structure

The active ingredient contained in Pari tablets is Paroxetine
Hydrochloride.
Each film-coated Pari tablet contains Paroxetine Hydrochloride
equivalent to 10 mg, 20 mg, 30 mg or 40 mg of Paroxetine.

Uses of Pari 10 mg, 20 mg, 30 mg and 40 mg Tablets:
Pari (Generic Paroxetine tablets) is a type of antidepressant known as an SSRI
(selective serotonin reuptake inhibitor).
Pari (Generic Paroxetine Hydrochloride Tablets) is used to treat depression,
obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety
disorder (GAD), social anxiety disorder (also known as social phobia),
premenstrual dysphoric disorder (PMDD), and posttraumatic stress disorder
(PTSD).
Paroxetine belongs to a group of medicines known as selective serotonin
reuptake inhibitors (SSRIs). These medicines are thought to work by increasing
the activity of the chemical called serotonin in the brain.
Paroxetine helps many people recover from depression, and it has fewer
unwanted effects than older antidepressants. It works by helping to restore the
balance of a certain natural substance (serotonin) in the brain.
URL: https://www.theswisspharmacy.com/product_info.php?info=p9722_Pari-Tablets.html

Uses of Pari 10 mg, 20 mg, 30 mg and 40 mg Tablets:
This medication may improve your mood, sleep, appetite, and energy
level and may help restore your interest in daily living.
It may decrease fear, anxiety, unwanted thoughts, and the number of
panic attacks.
It may also reduce the urge to perform repeated tasks (compulsions
such as hand-washing, counting, and checking) that interfere with daily
living.

Recommended Adult Dosage
Major Depressive Disorder: For most patients, the starting dose of
Pari Tablets (Generic Paroxetine Tablets) is 20 mg/day to be
administered as a single daily dose with or without food, usually in the
morning. Some patients not responding to a 20 mg dose may benefit from
dose increases, in 10 mg/day increments, up to a maximum of 50
mg/day.
Obsessive Compulsive Disorder: The recommended dose of Paroxetine
Hydrochloride tablets in the treatment of OCD is 40 mg daily administered
as a single daily dose with or without food, usually in the morning.
Patients should be started on 20 mg/day and the dose can be increased
in 10 mg/day increments. Dose changes should occur at intervals of at
least 1 week. Patients were dosed in a range of 20 to 60 mg/day in the
clinical trials.

Panic Disorder: The recommended starting dose of Paroxetine
Hydrochloride tablets (Pari) in the treatment of panic disorder is 10 mg/day
administered as a single daily dose with or without food, usually in the
morning. The target dose of Paroxetine tablets in the treatment of panic
disorder is 40 mg/day.
Dose changes should occur in 10 mg/day increments and at intervals of at
least 1 week. Patients were dosed in a range of 10 to 60 mg/day in the
clinical trials. The maximum dosage should not exceed 60 mg/day.
Social Anxiety Disorder: The recommended starting dose of Paroxetine
Hydrochloride tablets (Pari) in the treatment of social anxiety disorder is 20
mg/day administered as a single daily dose with or without food, usually in
the morning. Available information does not suggest any additional benefit
for doses above 20 mg/day.

Generalized Anxiety Disorder: The recommended starting dose of
Paroxetine Hydrochloride tablets (Pari) in the treatment of generalized
anxiety disorder is 20 mg/day administered as a single daily dose with or
without food, usually in the morning. There is no sufficient evidence to
suggest a greater benefit to doses higher than 20 mg/day.
Posttraumatic Stress Disorder: The recommended starting dose of
Paroxetine Hydrochloride tablets (Pari) in the treatment of posttraumatic
stress disorder is 20 mg/day administered as a single daily dose with or
without food, usually in the morning.
There was no sufficient evidence in a fixed dose study, to suggest a greater
benefit for a dose of 40 mg/day compared to 20 mg/day.
Dose changes, if indicated, should occur in 10 mg/day increments and at
intervals of at least 1 week.

Premenstrual Dysphoric Disorder: The recommended starting dose of Pari
(Generic Paroxetine Hydrochloride Tablets) in the treatment of
premenstrual dysphoric disorder is 12.5 mg/day administered as a single
daily dose with or without food, usually in the morning.
Pari may be administered either daily throughout the menstrual cycle or
limited to the luteal phase of the menstrual cycle, depending on physician
assessment. The recommended initial dose is 12.5 mg/day. During clinical
trials, both 12.5 mg/day and 25 mg/day were shown to be effective. Dose
changes should occur at intervals of at least 1 week.

Contraindications
➔
Pari tablets are contraindicated in patients with a known
hypersensitivity to Paroxetine Hydrochloride or any component
of the tablet.
➔
The use of MAOIs intended to treat psychiatric disorders with
Pari (Paroxetine Hydrochloride Tablets) or within 14 days of
stopping treatment with Paroxetine tablets is contraindicated
because of an increased risk of serotonin syndrome. The use of
Paroxetine tablets within 14 days of stopping an MAOI intended to
treat psychiatric disorders is also contraindicated.

Contraindications
➔
Starting Paroxetine tablets in a patient who is being treated with
MAOIs such as Linezolid or intravenous methylene blue is also
contraindicated because of an increased risk of serotonin
syndrome.
➔
Concomitant use in patients taking Pimozide or Thioridazine is
contraindicated.

Storage Instructions
Pari Tablets (Generic Paroxetine Hydrochloride
Tablets) have to be stored at controlled room
temperature i.e. from 20°C to 25°C (68°F to 77°F) with
excursions permitted between 15° to 30°C (59° to
86°F).
Keep this as well as all other medicines away from
children and pets.

Warnings
Increased risk of suicidal thoughts and behavior in pediatric and young
adult patients taking antidepressants. Closely monitor all
antidepressant-treated patients for clinical worsening and emergence of
suicidal thoughts and behaviors. Pari is not approved for use in pediatric
patients.
Serotonin Syndrome: Increased risk when co-administered with other
serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken
alone. If occurs, discontinue Pari (Generic Paroxetine Hydrochloride
Tablets) and initiate supportive measures.
Embryofetal and Neonatal Toxicity: Can cause fetal and neonatal harm.
Increased risk of cardiovascular malformations for exposure during the
first trimester. Exposure in late pregnancy may lead to an increased risk
for persistent pulmonary hypertension (PPNH) of the newborn.

Warnings
Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal
anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other
anticoagulant drugs may increase risk.
Activation of Mania/Hypomania: Screen patients for bipolar disorder.
Seizures: Use with caution in patients with seizure disorders.
Angle-Closure Glaucoma: Angle-closure glaucoma has occurred in
patients with untreated anatomically narrow angles treated with
antidepressants.

Possible Side Effects
Most common Pari (Paroxetine Hydrochloride Tablets) side effects
with an incidence rate of greater than or equal to 5% and at least
twice placebo in placebo-controlled MDD, PD, SAD, and PMDD
clinical trials: abnormal ejaculation, abnormal vision, asthenia,
constipation, decreasedappetite, diarrhea, dizziness, dry mouth,
female genital disorder, impotence, insomnia, libido decreased,
nausea, somnolence, sweating, tremor.

Pari Tablets Overdosage
Commonly reported adverse events associated with Paroxetine
Hydrochloride (Pari tablets) overdosage include somnolence, coma,
nausea, tremor, tachycardia, confusion, vomiting, and dizziness. Other
notable signs and symptoms observed with overdoses involving
paroxetine (alone or with other substances) include mydriasis, convulsions
(including status epilepticus), ventricular dysrhythmias (including torsades
de pointes), hypertension, aggressive reactions, syncope, hypotension,
stupor, bradycardia, dystonia, rhabdomyolysis, symptoms of hepatic
dysfunction (including hepatic failure, hepatic necrosis, jaundice, hepatitis,
and hepatic steatosis), serotonin syndrome, manic reactions, myoclonus,
acute renal failure, and urinary retention.

Treatment of Pari Tablets Overdosage
No specific antidotes for Paroxetine Hydrochloride (Pari Tablets) are known. Treatment
should consist of those general measures employed in the management of
overdosage with any drugs effective in the treatment of major depressive disorder.
Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and
vital signs. General supportive and symptomatic measures are also recommended.
Induction of emesis is not recommended.
Due to the large volume of distribution of this drug, forced diuresis, dialysis,
hemoperfusion, or exchange transfusion are unlikely to be of benefit.
A specific caution involves patients who are taking or have recently taken Paroxetine
who might ingest excessive quantities of a tricyclic antidepressant.
In such a case, accumulation of the parent tricyclic and/or an active metabolite may
increase the possibility of clinically significant sequelae and extend the time needed
for close medical observation. In managing overdosage, consider the possibility of
multiple drug involvement.

Pari Tablets During Pregnancy
Paroxetine Hydrochloride (Pari Tablets) has been classified by the US
FDA as Pregnancy Category D.
Epidemiological studies have shown that infants exposed to Paroxetine
Hydrochloride in the first trimester of pregnancy have an increased
risk of congenital malformations, particularly cardiovascular
malformations.
In case Paroxetine Hydrochloride (Pari Tablets) is used during
pregnancy, or if the patient becomes pregnant while taking Paroxetine,
advise the patient of the potential hazard to the fetus.

Pari Tablets (Generic Paroxetine Hydrochloride
Tablets) are manufactured by IPCA Laboratories
Limited, India.

Pari Tablets (Generic Paroxetine Hydrochloride Tablets)

Recommended

Recommended

More Related Content

Similar to Pari Tablets (Generic Paroxetine Hydrochloride Tablets)

Similar to Pari Tablets (Generic Paroxetine Hydrochloride Tablets) (20)

More from The Swiss Pharmacy

More from The Swiss Pharmacy (20)

Recently uploaded

Recently uploaded (20)

Pari Tablets (Generic Paroxetine Hydrochloride Tablets)